# US 2025/0152590 A1 · Nurr1:rxr activating compounds for simultaneous treatment of symptoms and pathology of parkinson's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152590 A1
- Document ID: US20250152590A1
- Status: Published application
- Kind: A1
- Application number: 18/815,726
- Filed: 2024-08-26
- Published: 2025-05-15
- Earliest claimed: 2015-10-20
- Inventors: Demetrios K. Vassilatis; Athanasios D. Spathis; Demesthenes Fokas
- Web page: https://patentgrep.com/patent/US20250152590A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 25/16: Anti-Parkinson drugs
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 487/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeuties to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the symptoms of such diseases and therefore represent a new treatment modality for ameliorating chronic and acute conditions. The compounds of the invention are capable of selectively potentiating the activity of the Nurr1:RXRα heterodimer, and are able to treat diseases or conditions associated with aberrant Nurr1:RXRα function. The invention further provides methods for treating neurodegenerative disorders by administration of Nurr1:RXRα activating agents.

## Claims

### Claim at position 1

-48. (canceled)

### Claim 49

A compound of formula 1e:
or a pharmaceutically acceptable salt thereof, wherein n is 0 to 2, p is 0 to 2;
each R1 is independently selected from the group consisting of halogen, cyanate, isocyanate, thiocyanate, isothiocyanate, selenocyanate, isoselenocyanate, alkoxy, trifluoromethoxy, azido, cyano, nitro, hydroxy, acyl, mercapto, carboxyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —OR7, —SR7, and —N(R8) R7;
each R2 is independently selected from the group consisting of halogen, cyanate, isocyanate, thiocyanate, isothiocyanate, selenocyanate, isoselenocyanate, alkoxy, trifluoromethoxy, azido, cyano, nitro, hydroxy, acyl, mercapto, carboxyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —OR7, —SR7, and —N(R8) R7;
R4 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aryl-alkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted heteroaryl-alkyl, optionally substituted heterocyclolalkyl, OR7, and —N(R8) R7;
R5 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted aryl;
each R7 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted aryl-alkyl, and optionally substituted heterocyclyl; and
each R8 is independently selected from the group consisting of hydrogen and optionally substituted alkyl;
R10 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aryl-alkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; and
R11 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aryl-alkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl.

### Claim 50 (depends on 49)

The compound of claim 49, wherein R4 is methyl or trifluoromethyl.

### Claim 51 (depends on 49)

The compound of claim 49, wherein R5 is hydrogen or alkyl.

### Claim 52 (depends on 49)

The compound of claim 49, wherein n is 0 or 1, and wherein p is 0 or 1.

### Claim 53 (depends on 49)

The compound of claim 49, wherein R4 is haloalkyl.

### Claim 54 (depends on 49)

The compound of claim 49, wherein R4 is trifluoromethyl.

### Claim 55 (depends on 49)

A compound of claim 49 selected from the group consisting of:
(a)
(b)
and
(c)
or a salt or free base thereof.

### Claim 56 (depends on 49)

A pharmaceutical composition comprising a compound of claim 49 and a pharmaceutically acceptable excipient.

### Claim 57 (depends on 56)

The pharmaceutical composition of claim 56, wherein said pharmaceutical composition comprises an additional therapeutically active compound.

### Claim 58 (depends on 57)

The pharmaceutical composition of claim 57, wherein said additional therapeutically active compound is selected from the group consisting of levodopa (L-dihydroxyphenylalanine), L-aromatic amino acid decarboxylase (AADC) inhibitors, and catechol O-methyl transferase (COMT) inhibitors.

### Claim 59 (depends on 49)

A method of treating a neurodegenerative disorder in a human, or alleviating or preventing one or more symptoms of a neurodegenerative disorder in a human, said method comprising administering to the human an effective amount of a compound of claim 49.

### Claim 60 (depends on 59)

The method of claim 59, wherein said symptom is selected from the group consisting of bradykinesia and dyskinesias.

### Claim 61 (depends on 59)

The method of claim 59, wherein said symptom is selected from the group consisting of anxiety and depression.

### Claim 62 (depends on 59)

The method of claim 59, wherein said symptom is selected from the group consisting of learning difficulties, memory disorders, and attention deficit disorder.

### Claim 63 (depends on 59)

The method of claim 59, wherein said symptom is selected from the group consisting of insomnia and katalepsy.

### Claim 64 (depends on 59)

The method of claim 59, wherein said disorder is Parkinson's disease.

### Claim 65 (depends on 59)

The method of claim 59, wherein the effective amount is sufficient to halt or prevent degeneration of neurons.

### Claim 66 (depends on 65)

The method of claim 65, wherein said neurons are dopaminergic midbrain neurons.

### Claim 67 (depends on 59)

The method of claim 59, wherein the effective amount is sufficient to increase the rate of dopamine biosynthesis.
